Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2- breast cancer (LEADER). - Spring LM; Scarpetti L; Medford AJ; Niemierko A; Comander A; Mulvey T; Schnipper L; Isakoff SJ; Moy B; Wander SA; Shin J; Ephrem Z; et al. (NPJ breast cancer, 2025)